These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23711544)

  • 1. Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study.
    Krause K; Mahamed A; Weller K; Metz M; Zuberbier T; Maurer M
    J Allergy Clin Immunol; 2013 Sep; 132(3):751-754.e5. PubMed ID: 23711544
    [No Abstract]   [Full Text] [Related]  

  • 2. Refractory urticarial vasculitis responsive to anti-B-cell therapy.
    Mukhtyar C; Misbah S; Wilkinson J; Wordsworth P
    Br J Dermatol; 2009 Feb; 160(2):470-2. PubMed ID: 19120327
    [No Abstract]   [Full Text] [Related]  

  • 3. Non-complementaemic urticarial vasculitis: successful treatment with the IL-1 receptor antagonist, anakinra.
    Botsios C; Sfriso P; Punzi L; Todesco S
    Scand J Rheumatol; 2007; 36(3):236-7. PubMed ID: 17657682
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hypocomplementemic vasculitis treated with dapsone].
    Hérault M; Mazet J; Beurey P; Cuny JF; Barbaud A; Schmutz JL; Bursztejn AC
    Ann Dermatol Venereol; 2010; 137(8-9):541-5. PubMed ID: 20804899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urticarial vasculitis: a unique presentation.
    Stigall LE; Sigmon JR; Leicht SS
    South Med J; 2009 May; 102(5):531-3. PubMed ID: 19373142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of reserpine as "add-on therapy" to antihistamines in patients with recalcitrant chronic idiopathic urticaria and urticarial vasculitis.
    Demitsu T; Yoneda K; Kakurai M; Sasaki K; Hiratsuka Y; Azuma R; Yamada T; Umemoto N
    J Dermatol; 2010 Sep; 37(9):827-9. PubMed ID: 20883370
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypocomplementaemic urticarial vasculitis: successful treatment with cyclophosphamide-dexamethasone pulse therapy.
    Worm M; Muche M; Schulze P; Sterry W; Kolde G
    Br J Dermatol; 1998 Oct; 139(4):704-7. PubMed ID: 9892919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypocomplementaemic urticarial vasculitis with bullous lesions and pericardial involvement].
    Kervarrec T; Binois R; Bléchet C; Estève É
    Ann Dermatol Venereol; 2015 Oct; 142(10):557-62. PubMed ID: 25613197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes.
    Lachmann HJ; Lowe P; Felix SD; Rordorf C; Leslie K; Madhoo S; Wittkowski H; Bek S; Hartmann N; Bosset S; Hawkins PN; Jung T
    J Exp Med; 2009 May; 206(5):1029-36. PubMed ID: 19364880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.
    de Koning HD; Schalkwijk J; van der Ven-Jongekrijg J; Stoffels M; van der Meer JW; Simon A
    Ann Rheum Dis; 2013 Oct; 72(10):1634-8. PubMed ID: 23087179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urticarial vasculitis treated with colchicine.
    Wiles JC; Hansen RC; Lynch PJ
    Arch Dermatol; 1985 Jun; 121(6):802-5. PubMed ID: 4004306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urticarial vasculitis: a retrospective study of 15 cases.
    Moreno-Suárez F; Pulpillo-Ruiz Á; Zulueta Dorado T; Conejo-Mir Sánchez J
    Actas Dermosifiliogr; 2013 Sep; 104(7):579-85. PubMed ID: 23891451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study.
    Brik R; Butbul-Aviel Y; Lubin S; Ben Dayan E; Rachmilewitz-Minei T; Tseng L; Hashkes PJ
    Arthritis Rheumatol; 2014 Nov; 66(11):3241-3. PubMed ID: 25049046
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypocomplementemic urticarial vasculitis arising in a patient with immunoglobulin G4-related disease.
    Takao M; Hamada T; Kaji T; Ikeda-Mizuno K; Takehara-Yasuhara C; Ichimura K; Yanai H; Yshino T; Iwatsuki K
    Int J Dermatol; 2016 Apr; 55(4):430-3. PubMed ID: 26276260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin therapy for hypocomplementemic urticarial vasculitis associated with systemic lupus erythematosus in a child.
    Yamazaki-Nakashimada MA; Duran-McKinster C; Ramírez-Vargas N; Hernandez-Bautista V
    Pediatr Dermatol; 2009; 26(4):445-7. PubMed ID: 19689522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypocomplementemic urticarial vasculitis syndrome].
    Sessler R; Hasche G; Olbricht CJ
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):1003-6. PubMed ID: 11004912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged urticaria with purpura: the spectrum of clinical and histopathologic features in a prospective series of 22 patients exhibiting the clinical features of urticarial vasculitis.
    Lee JS; Loh TH; Seow SC; Tan SH
    J Am Acad Dermatol; 2007 Jun; 56(6):994-1005. PubMed ID: 17504716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urticarial vasculitis--response to gold therapy.
    Handfield-Jones SE; Greaves MW
    J R Soc Med; 1991 Mar; 84(3):169. PubMed ID: 2013901
    [No Abstract]   [Full Text] [Related]  

  • 19. Urticarial vasculitis secondary to H1N1 vaccination.
    Hughes R; Lacour JP; Baldin B; Reverte M; Ortonne JP; Passeron T
    Acta Derm Venereol; 2010 Nov; 90(6):651-2. PubMed ID: 21057759
    [No Abstract]   [Full Text] [Related]  

  • 20. CANTOS - is selective targeting of inflammation in atherosclerosis enough?
    Misra DP; Agarwal V
    J R Coll Physicians Edinb; 2018 Sep; 48(3):246-247. PubMed ID: 30191914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.